Effect of amlodipine on platelet inhibition by clopidogrel in patients with ischaemic heart disease: A randomised, controlled trial

Heart

Volumn 99, Issue 7, 2013, Pages 468-473

  Li, Andrew Y W ^a   Ng, Fook Hong ^a   Chan, Francis K L ^b   Tunggal, Prabowo ^a   Chan, Kit ^a   Lau, Yuk Kong ^a  

^a RUTTONJEE HOSPITAL   (Hong Kong)

^b CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; AMILORIDE PLUS HYDROCHLOROTHIAZIDE; AMIODARONE; AMLODIPINE BESYLATE; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CLOPIDOGREL; CYTOCHROME P450; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FUROSEMIDE; GINKGO BILOBA EXTRACT; HEPARIN; HYDRALAZINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INDAPAMIDE; ISOSORBIDE MONONITRATE; PANTOPRAZOLE; PURINERGIC P2Y12 RECEPTOR; SPIRONOLACTONE;

AGED; ARTICLE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG EFFICACY; FEMALE; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; OPEN STUDY; PLATELET INHIBITION; PLATELET REACTIVITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; THROMBOCYTE FUNCTION; TREATMENT RESPONSE;

AGED; AGED, 80 AND OVER; AMLODIPINE; CALCIUM CHANNEL BLOCKERS; CHI-SQUARE DISTRIBUTION; CYTOCHROME P-450 ENZYME SYSTEM; DRUG INTERACTIONS; ENZYME INHIBITORS; FEMALE; HONG KONG; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL ISCHEMIA; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; PLATELET FUNCTION TESTS; PURINERGIC P2Y RECEPTOR ANTAGONISTS; RECEPTORS, PURINERGIC P2Y12; RISK ASSESSMENT; RISK FACTORS; TICLOPIDINE; TIME FACTORS;

EID: 84875231920     PISSN: 13556037     EISSN: 1468201X     Source Type: Journal    
DOI: 10.1136/heartjnl-2012-302801     Document Type: Article

References (43)

1. O'Connor CM, Carson PE, Miller AB. Effect of amlodipine on mode of death among patients with advanced heart failure in the PRAISE trial. prospective Randomized Amlodipine Survival Evaluation. Am J Cardiol 1998;82:881-7. (Pubitemid 28467363)
2. Elkayam U, Amin J, Mehra A, et al. A prospective, randomized, double-blind, crossover study to compare the efficacy and safety of chronic nifedipine therapy with that of isosorbide dinitrate and their combination in the treatment of chronic congestive heart failure. Circulation 1990;82:1954-61.
3. Kazui M, Nishiya Y, Ishizuka T, et al. Identification of the human cytochrome P450 enzymes involved in the two oxidative steps in the bioactivation of clopidogrel to its pharmacologically active metabolite. Drug Metab Dispos 2010;38:92-9.
4. Siller-Matula J, Schror K, Wojta J, et al. Thienopyridines in cardiovascular disease: focus on clopidogrel resistance. Thromb Haemost 2007;97:385-93. (Pubitemid 46437800)
5. Harmsze AM, Robijns K, Van Werkum JW, et al. The use of amlodipine, but not of P-glycoprotein inhibiting calcium channel blockers is associated with clopidogrel poor-response. Thromb Haemost 2010;103:920-5.
6. Siller-Matula JM, Lang I, Christ G, et al. Calcium-channel blockers reduce the antiplatelet effect of clopidogrel. J Am Coll Cardiol 2008;52:1557-63.
7. Gremmel T, Steiner S, Seidinger D, et al. Calcium-channel blockers decrease clopidogrel-mediated platelet inhibition. Heart 2010;96:186-9.
8. Sarafoff N, Neumann L, Morath T, et al. Lack of impact of calcium-channel blockers on the pharmacodynamic effect and the clinical efficacy of clopidogrel after drug-eluting stenting. Am Heart J 2011;161:605-10.
9. Olesen JB, Gislason GH, Charlot MG, et al. Calcium-channel blockers do not alter the clinical efficacy of clopidogrel after myocardial infarction: a nationwide cohort study. J Am Coll Cardiol 2011;57:409-17.
10. Good CW, Steinhubl SR, Brennan DM, et al. Is there a clinically significant interaction between calcium channel antagonists and clopidogrel?: results from the Clopidogrel for the Reduction of Events During Observation (CREDO) trial. Circ Cardiovasc Interv 2012;5:77-81.
11. Lin JH, Lu AYH. Inhibition and induction of cytochrome P450 and the clinical implications. Clin Pharmacokinet 1998;35:361-90. (Pubitemid 28520008)
12. Katoh M, Nakajima M, Shimada N, et al. Inhibition of human cytochrome P450 enzymes by 1, 4-dihydropyridine calcium antagonists: prediction of in vivo drug-drug interactions. Eur J Clin Pharmacol 2000;55:843-52. (Pubitemid 30201767)
13. Ma B, Prueksaritanont T, Lin JH. Drug interactions with calcium channel blockers: possible involvement of metabolite-intermediate complexation with CYP3A. Drug Metab Dispos 2000;28:125-30. (Pubitemid 30068994)
14. Zhou SF, Xue CC, Yu XQ, et al. Clinically important drug interactions potentially involving mechanism-based inhibition of cytochrome P450 3A4 and the role of therapeutic drug monitoring. Ther Drug Monit 2007;29:687-710. (Pubitemid 350190847)
15. Kelly JG, O'Malley K. Clinical pharmacokinetics of calcium antagonists: An update. Clin Pharmacokinet 1992;22:416-33.
16. Bouman HJ, Parlak E, Van Werkum JW, et al. Which platelet function test is suitable to monitor clopidogrel responsiveness? A pharmacokinetic analysis on the active metabolite of clopidogrel. J Thromb Haemost 2010;8:482-8.
17. Bonello L, Tantry US, Marcucci R, et al. Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate. J Am Coll Cardiol 2010;56:919-33.
18. Sibbing D, Byrne RA, Bernlochner I, et al. High platelet reactivity and clinical outcome-fact and fiction. Thromb Haemost 2011;106:191-202.
19. Marcucci R, Gori AM, Paniccia R, et al. Cardiovascular death and nonfatal myocardial infarction in acute coronary syndrome patients receiving coronary stenting are predicted by residual platelet reactivity to ADP detected by a point-of-care assay: a 12-month follow-up. Circulation 2009;119:237-42.
20. Cuisset T, Hamilos M, Sarma J, et al. Relation of low response to clopidogrel assessed with point-of-care assay to periprocedural myonecrosis in patients undergoing elective coronary stenting for stable angina pectoris. Am J Cardiol 2008;101:1700-3.
21. Valgimigli M, Campo G, De Cesare N, et al. Tailoring Treatment With Tirofiban in Patients Showing Resistance to Aspirin and/or Resistance to Clopidogrel (3T/2R) Investigators. Intensifying platelet inhibition with tirofiban in poor responders to aspirin, clopidogrel, or both agents undergoing elective coronary intervention: results from the double-blind, prospective, randomized Tailoring Treatment with Tirofiban in Patients Showing Resistance to Aspirin and/or Resistance to Clopidogrel study. Circulation 2009;119:3215-22.
22. Patti G, Nusca A, Mangiacapra F, et al. Point-of-care measurement of clopidogrel responsiveness predicts clinical outcome in patients undergoing percutaneous coronary intervention results of the ARMYDA-PRO (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty-Platelet Reactivity Predicts Outcome) study. J Am Coll Cardiol 2008;52:1128-33.
23. Breet NJ, Van Werkum JW, Bouman HJ, et al. Comparison of platelet function tests in predicting clinical outcome in patients undergoing coronary stent implantation. JAMA 2010;303:754-62.
24. Malinin A, Pokov A, Swaim L, et al. Validation of a verifynow-P2Y12 cartridge for monitoring platelet inhibition with clopidogrel. Methods: Find Exp Clin Pharmaco 2006;28:315-22. (Pubitemid 44047198)
25. Geisler T, Kapp M, Gohring-Frischholz K, et al. Residual platelet activity is increased in clopidogrel-and ASA-treated patients with coronary stenting for acute coronary syndromes compared with stable coronary artery disease. Heart 2008;94:743-7. (Pubitemid 351744692)
26. Ang L, Palakodeti V, Khalid A, et al. Elevated plasma fibrinogen and diabetes mellitus are associated with lower inhibition of platelet reactivity with clopidogrel. J Am Coll Cardiol 2008;52:1052-9.
27. Angiolillo DJ, Bernardo E, Ramirez C, et al. Insulin therapy is associated with platelet dysfunction in patients with type 2 diabetes mellitus on dual oral antiplatelet treatment. J Am Coll Cardiol 2006;48:298-304. (Pubitemid 44026661)
28. Carr ME. Diabetes mellitus: a hypercoagulable state. J Diabetes Complications 2001;15:44-54. (Pubitemid 32203891)
29. Ferriera IA, Mocking AI, Feijge MA, et al. Platelet inhibition by insulin is absent in type 2 diabetes mellitus. Arterioscler Thromb Vasc Biol 2006;26:417-22. (Pubitemid 43732209)
30. Winocour PD, Watala C, Perry DW, et al. Decreased platelet membrane fluidity due to glycation or acetylation of membrane proteins. Thromb Haemost 1992;68:577-82.
31. Mega JL, Close SL, Wiviott SD, et al. Cytochrome P-450 polymorphisms and response to clopidogrel. N Engl J Med 2009;360:354-62.
32. Sibbing D, Braun S, Morath T, et al. Platelet reactivity after clopidogrel treatment assessed with point-of-care analysis and early drug-eluting stent thrombosis. J Am Coll Cardiol 2009;53:849-56.
33. Desta Z, Zhao X, Shin JG, et al. Clinical significance of the cytochrome P450 2C19 genetic polymorphism. Clin Pharmacokinet 2002;41:913-58. (Pubitemid 35168437)
34. Food and Drug Administration. Reduced effectiveness of Plavix (clopidogrel) in patients who are poor metabolizers of the drug. FDA drug safety communication. http://www.fda.gov/Drugs/DrugSafety/ PostmarketDrugSafetyInformationforPatientsandProviders/ucm203888.htm.
35. Wang H, Tompkins LM. CYP2B6: new insights into a historically overlooked cytochrome P450 isozyme. Curr Drug Metab 2008;9:598-610.
36. Geick A, Eichelbaum M, Burk O. Nuclear receptor response elements mediate induction of intestinal MDR1 by rifampin. J Biol Chem 2001;276:14581-7.
37. Wang H, Faucette SR, Gilbert D, et al. Glucocorticoid receptor enhancement of pregnane X receptor-mediated CYP2B6 regulation in primary human hepatocytes. Drug Metab Dispos 2003;31:620-30. (Pubitemid 36444171)
38. Ferguson SS, Le Cluyse EL, Negishi M, et al. Regulation of human CYP2C9 by the constitutive androstane receptor: discovery of a new distal binding site. Mol Pharmacol 2002;62:737-46. (Pubitemid 36329394)
39. Mehlotra RK, Ziats MN, Bockarie MJ, et al. Prevalence of CYP2B6 alleles in malaria-endemic populations of West Africa and Papua New Guinea. Eur J Clin Pharmacol 2006;62:267-75.
40. Lang T, Klein K, Fischer J, et al. Extensive genetic polymorphism in the human CYP2B6 gene with impact on expression and function in human liver. Pharmacogenetics 2001;11:399-415. (Pubitemid 32656581)
41. Guan S, Huang M, Li X, et al. Intra-and inter-ethnic differences in the allele frequencies of cytochrome P450 2B6 gene in Chinese. Pharm Res 2006;23:1983-90.
42. Bouman HJ, Harmsze AM, Van Werkum JW, et al. Variability in on-treatment platelet reactivity explained by CYP2C19*2 genotype is modest in clopidogrel pretreated patients undergoing coronary stenting. Heart 2011;97:1239-44.
43. Guengerich FP, Peterson LA, Böcker RH. Cytochrome P-450-catalyzed hydroxylation and carboxylic acid ester cleavage of hantzsch pyridine esters. J Biol Chem 1988;263:8176-83.